MAGE-1 (222-231)

MAGE-1 (222-231) is a synthetic peptide fragment derived from the melanoma-associated antigen 1 (MAGE-1) protein, specifically encompassing amino acid residues 222 to 231. As a class I major histocompatibility complex (MHC)-restricted epitope, this peptide is recognized for its relevance in tumor immunology and antigen presentation studies. Its sequence is highly conserved within the MAGE family, which is predominantly expressed in various tumor cells but largely absent in normal tissues except for the testis. Researchers utilize this peptide to probe immune recognition mechanisms, evaluate T-cell responses, and investigate the molecular basis of tumor antigenicity, making it a valuable tool in cancer immunology and epitope mapping research.

Antigen presentation studies: MAGE-1 (222-231) is widely used to investigate the molecular mechanisms underlying antigen processing and presentation by MHC class I molecules. By pulsing antigen-presenting cells with this defined peptide epitope, researchers can assess the efficiency of peptide loading onto HLA molecules and monitor subsequent recognition by cytotoxic T lymphocytes (CTLs). Such studies are critical for elucidating the pathways by which tumor-associated antigens are displayed to the immune system, advancing the understanding of immune surveillance in cancer.

T-cell activation assays: The peptide serves as a model antigen for evaluating CD8+ T-cell responses in vitro. When presented by compatible HLA alleles, MAGE-1 (222-231) can stimulate antigen-specific CTLs derived from patient samples or established T-cell clones. This application is pivotal for measuring T-cell functionality, cytotoxicity, and cytokine release in response to tumor-associated epitopes, supporting the development of immunological assays and the characterization of T-cell receptor specificity.

Epitope mapping and validation: Researchers employ MAGE-1 (222-231) to precisely define T-cell epitopes within the MAGE-1 protein and related cancer-testis antigens. Systematic use of this peptide in mapping experiments allows for the identification and validation of immunodominant regions recognized by the adaptive immune system. Such insights are fundamental for designing targeted immunotherapeutic strategies and refining antigen selection in preclinical research.

Peptide-MHC binding studies: The defined sequence and high purity of MAGE-1 (222-231) make it an ideal candidate for quantitative analyses of peptide-MHC interactions. Utilizing binding assays, structural biochemistry approaches, or computational modeling, researchers can dissect the affinity and stability of the peptide-HLA complex. These studies inform the rational design of peptide-based vaccines and enhance understanding of the structural determinants governing immune recognition.

Immunological reagent development: The peptide is frequently incorporated as a positive control or reference antigen in the generation and validation of immunological reagents, such as peptide-MHC multimer complexes and T-cell detection kits. Its well-characterized immunogenicity and defined sequence make it a reliable tool for calibrating assay sensitivity, optimizing reagent performance, and standardizing protocols across laboratories engaged in tumor immunology research.

1. GLP-1, exendin-4 and C-peptide regulate pancreatic islet microcirculation, insulin secretion and glucose tolerance in rats

2. Odorant binding protein based biomimetic sensors for detection of alcohols associated with Salmonella contamination in packaged beef

3. Olfactory receptor based piezoelectric biosensors for detection of alcohols related to food safety applications

4. The spatiotemporal control of signalling and trafficking of the GLP-1R

5. The effect of B-type allatostatin neuropeptides on crosstalk between the insect immune response and cold tolerance